Indian Parliament Panel Urges Rejection Of MNC Anti-Generics Try
This article was originally published in PharmAsia News
An effort by multinational pharmaceutical companies to get India to require separate research before approving generic versions of their drugs has suffered a setback in the Parliament. A committee urged India's drug authorities to keep the current practice of approving generics that rely on the same chemical composition as a branded version already approved in another country. Under the current rules, Indian generics makers need only refer to the branded drug and show it uses the same chemical makeup if the generic wants to win marketing approval. The committee said changes in the rule were being urged by MNCs with a vested interest in new rules. (Click here for more
You may also be interested in...
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.